One Pathway, Four Very Different Clinical Stories

TERN-601 Lost 4.6% More Weight Than Placebo. Three Liver Cases Ended the Program.

A peer-reviewed Phase 2 trial explains why the oral GLP-1 candidate TERN-601 was discontinued: modest weight loss, high dropout, and three delayed liver-enzyme cases.

GLP-1 Drugs Were Linked to 26% Less Dementia in High-Risk Adults. The Alzheimer’s Trials Still Failed.

A new study found lower dementia incidence in adults with diabetes and mild cognitive impairment. It is promising observational evidence, not proof of prevention.

Ribupatide’s First Human Paper Reports 9.6% Weight Loss in Four Weeks. The Trial Was Tiny.

A new peer-reviewed Phase 1 paper puts hard numbers behind ribupatide, a weekly dual GLP-1/GIP peptide. The strongest result is striking, but eight-person dose groups and four weeks of treatment leave the real obesity question open.

Avexitide Cut Dangerous Low-Blood-Sugar Events by 55%. Full Phase 3 Data Are Still Missing.

A 78-person Phase 3 trial found 55% fewer Level 2 and Level 3 hypoglycemic events with avexitide. The signal is strong, but the complete dataset is not public.

The GLP-1 pathway did not give us one tidy story this week. It gave us four. An oral agonist produced measurable weight loss and then failed its benefit-risk test. A large health-record analysis linked GLP-1 treatment to fewer dementia diagnoses in a narrow high-risk group, while randomized Alzheimer’s trials remained negative. A new dual agonist posted a striking four-week result in very few people. And a GLP-1 antagonist—not an agonist—reduced dangerous hypoglycemia after bariatric surgery.

That spread is useful because it exposes a recurring mistake in metabolic medicine: treating a receptor label as if it were a verdict. TERN-601, semaglutide, ribupatide, tirzepatide, and avexitide all touch incretin biology, but they differ in chemistry, direction of action, population, endpoint, and evidence quality. The practical question is never just, “Does it involve GLP-1?” It is which molecule, for whom, at what exposure, and supported by what kind of trial.

The numbers this week are worth reading, but only with their denominators and design limits attached. A 4.6% placebo-adjusted weight change came with three delayed liver cases. A 26% relative dementia association translated to a 4.9 percentage-point absolute difference and remained observational. A 9.6% weight drop came from an eight-person dose group. A 55% reduction in hypoglycemic events came from a positive Phase 3 trial whose full tables are not yet public. Here is what each result actually changes.

TERN-601: efficacy could not outrun the liver signal

TERN-601 was a once-daily, oral, non-peptide GLP-1 receptor agonist tested in the 12-week FALCON Phase 2 study. Among 167 adults with obesity or overweight without diabetes, the standard 500 mg schedule produced 4.9% mean weight loss versus 0.3% with placebo, a 4.6 percentage-point adjusted difference. Nearly half of that group reached at least 5% weight loss. The 750 mg group did not do better, and 24.6% of participants assigned to active treatment discontinued early. That is a real pharmacologic effect, but not an unusually strong one in today’s obesity market.

The decisive finding was delayed liver injury. Three participants developed ALT or AST elevations beginning at week eight or later, with peaks appearing weeks after the last dose. Independent review considered two cases consistent with potential drug-induced liver injury; one was supported by biopsy, and one participant showed a potential Hy’s Law pattern. All abnormalities resolved without treatment, but reversibility does not erase a warning signal in a medicine intended for chronic use. The program was discontinued because moderate benefit no longer justified uncertain liver risk.

The correct class-level conclusion is narrow. TERN-601 is a small molecule with chemistry and metabolism that differ from peptide drugs such as semaglutide and tirzepatide. Its failure does not show that all GLP-1 medicines injure the liver. It does show why oral convenience cannot substitute for molecule-specific safety data, longer monitoring, and follow-up after dosing ends. Related oral small molecules have produced liver concerns before, so a clean short Phase 1 study is not enough to settle the issue.

Dementia risk: a useful association, not a prevention claim

A target-trial emulation compared 660 adults starting a GLP-1 receptor agonist with 660 matched adults starting a DPP-4 inhibitor. Everyone had type 2 diabetes and mild cognitive impairment but no dementia at baseline. Over follow-up of up to five years, 101 people in the GLP-1 group and 132 in the comparator group received a dementia diagnosis. The hazard ratio was 0.74, or a 26% lower relative rate. Estimated cumulative incidence was 15.5% versus 20.4%, an absolute difference of 4.9 percentage points.

The design used propensity matching and several sensitivity analyses, which makes the signal more credible than a raw database comparison. It still cannot remove unmeasured differences in frailty, access to care, adherence, cardiovascular risk, kidney function, or the reasons clinicians chose one drug class over another. Electronic records also capture coded dementia diagnoses, not uniform biomarker-confirmed Alzheimer’s disease. Better glucose, weight, vascular, or stroke outcomes could affect dementia incidence without directly changing amyloid or tau pathology.

That distinction matters because the randomized EVOKE and EVOKE+ trials enrolled 3,808 people with amyloid-confirmed early Alzheimer’s disease and found that oral semaglutide did not slow cognitive or functional decline over 104 weeks. The studies are not contradictory: one asks whether GLP-1 therapy may reduce upstream metabolic and vascular pressure before dementia in people with diabetes; the others asked whether semaglutide treats established symptomatic Alzheimer’s disease. For now, the observational result justifies a dedicated prevention trial. It does not justify prescribing semaglutide for memory protection.

Ribupatide: a strong early signal in a very small trial

Ribupatide, also known as HRS9531 or KAI-9531, is a weekly peptide that activates both GLP-1 and GIP receptors. Its first full peer-reviewed human paper covered 90 healthy Chinese adults across single- and multiple-dose cohorts. In the four-dose portion, the highest titration group lost a mean 7.7 kg, or 9.6% of body weight, by day 29. Placebo lost 1.2 kg, or 1.4%. The pharmacokinetics supported weekly dosing: after the fourth dose, mean half-life was roughly seven to eight days.

The denominator keeps the result in proportion. Each active multiple-dose cohort began with eight people, and the pooled placebo group had six. Participants were healthy volunteers rather than a representative obesity population, baseline weights varied sharply between groups, and the study was designed primarily for safety and pharmacokinetics—not to prove weight-loss efficacy. Mild or moderate adverse events and no serious events are reassuring for an initial exposure study, but four injections cannot characterize uncommon or long-term harms.

Ribupatide shares the broad GLP-1/GIP target pair used by tirzepatide, but that does not make the molecules interchangeable or establish superiority. Sponsor-reported later studies suggest larger and longer weight-loss effects, and a 76-week global Phase 3 program is recruiting. Those trials need to show discontinuations, complete adverse-event data, body-composition changes, durability, and performance across thousands of people. The 9.6% result is a credible pharmacodynamic signal. It is not a dosing template, an approved treatment, or a head-to-head win.

Avexitide: blocking GLP-1 for a specific postsurgical problem

Avexitide reverses the usual GLP-1 framing. It is a 31-amino-acid peptide antagonist designed to block excessive GLP-1 signaling after bariatric surgery. In susceptible people, rapid nutrient delivery can trigger an exaggerated GLP-1 response, too much insulin, and a glucose crash one to three hours after a meal. Severe post-bariatric hypoglycemia can cause confusion, loss of coordination, seizures, or loss of consciousness. This is a narrow treatment target, not another route to weight loss.

In the randomized, double-blind LUCIDITY Phase 3 trial, 78 adults with hypoglycemia after Roux-en-Y gastric bypass received 90 mg avexitide once daily or placebo for 16 weeks. The sponsor reported a 55% relative reduction in the combined rate of Level 2 events below 54 mg/dL and Level 3 events requiring help, with p=0.000003. Most adverse events were mild or moderate, no serious event was attributed to treatment, and body weight remained stable. Earlier controlled studies pointed in the same direction.

The result clears an important efficacy threshold, but the public evidence is still incomplete. We do not yet have absolute event rates, confidence intervals, participant-level response data, or full safety tables. The controlled period was short for a chronic condition, and the pivotal population should not automatically be generalized to every type of gastrointestinal surgery. Amylyx plans an FDA submission by the end of 2026. Until regulators and independent reviewers can inspect the full package, avexitide remains investigational.